Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00813384 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT00813384 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 54 participants.
The verdict
NCT00813384, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
First in human, open-label, sequential dose escalation and expansion study of AMG 208 in subjects with advanced solid tumors.
Interventions
- DRUG AMG 208
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2008-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00813384
The ClinicalTrials.gov registry entry for NCT00813384 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 208 is the first listed.
NCT00813384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00813384 about?
NCT00813384 is a clinical study titled "A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors". First in human, open-label, sequential dose escalation and expansion study of AMG 208 in subjects with advanced solid tumors.
What is the current status of trial NCT00813384?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2008-12. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00813384?
The interventions under investigation include: AMG 208 (DRUG).
Who is sponsoring clinical trial NCT00813384?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.